Cargando…
Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma
BACKGROUND: Standard of care treatment options at glioblastoma relapse are still not well defined. Few studies indicate that the combination of trofosfamide plus etoposide may be feasible in pediatric glioblastoma patients. In this retrospective analysis, we determined tolerability and feasibility o...
Autores principales: | Schmidt, Teresa, Agkatsev, Sarina, Feldheim, Jonas, Oster, Christoph, Blau, Tobias, Sure, Ulrich, Keyvani, Kathy, Kleinschnitz, Christoph, Stuschke, Martin, Herrmann, Ken, Deuschl, Cornelius, Scheffler, Björn, Kebir, Sied, Glas, Martin, Lazaridis, Lazaros |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403750/ https://www.ncbi.nlm.nih.gov/pubmed/37547266 http://dx.doi.org/10.1093/noajnl/vdad090 |
Ejemplares similares
-
Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005–2022
por: Oster, Christoph, et al.
Publicado: (2023) -
Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma
por: Lazaridis, Lazaros, et al.
Publicado: (2022) -
Telemedicine in Neuro-Oncology—An Evaluation of Remote Consultations during the COVID-19 Pandemic
por: Feldheim, Jonas, et al.
Publicado: (2023) -
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022) -
Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma
por: Schmidt, Teresa, et al.
Publicado: (2021)